Table 3.

Treatment-related adverse events after SAbR and High-Dose IL-2 treatment

		Grade 3–4
Adverse event	Any Grade	SAbR and HD IL-2 (n = 30)	HD IL-2 Historical Control (n = 95)*	P
All adverse events	30 (100%)	22 (73.3%)	-	-
Cardiac	22 (73.3%)	3 (10.0%)	8 (8.4%)	0.72
Constitutional	27 (90.0%)	0 (0.0%)	3 (3.2%)	1
Gastrointestinal	22 (73.3%)	1 (3.3%)	9 (9.5%)	0.45
Hematology/Coagulation	28 (93.3%)	8 (26.7%)	13 (13.7%)	0.16
Hepatobiliary disorders	19 (63.3%)	3 (10.0%)	11 (11.6%)	1
Hypotension	18 (60.0%)	2 (6.7%)	54 (56.8%)	<0.0001
Infection	5 (16.7%)	3 (10.0%)	3 (3.2%)	0.15
Neurologic	12 (40.0%)	1 (3.3%)	14 (14.7%)	0.12
Other	14 (46.7%)	1 (3.3%)#	-	-
Psychiatric	6 (20.0%)	0 (0.0%)	0 (0.0%)	-
Renal/electrolytes	29 (96.7%)	11 (36.6%)	13 (13.7%)	0.0083
Respiratory	13 (43.3%)	3 (10.0%)	13 (13.7%)	0.76
Skin	21 (70.0%)	0 (0.0%)	-	-

^*McDermott et. al. JCO 2005 [4]

^#Leukocytopenia